Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Teen founders raise $6M to reinvent pesticides using AI — and convince Paul Graham to join in

From TechCrunch

By Jagmeet Singh

November 13, 2025

Teen founders raise $6M to reinvent pesticides using AI — and convince Paul Graham to join in

Teen founders raise $6M to reinvent pesticides using AI — and convince Paul Graham to join in

Two teenage founders walked into Y Combinator co-founder Paul Graham’s backyard with an idea no one in agriculture seemed to want — an AI model to help design better pesticides. By the time they left, they had a new business model, a new company, and eventually, Graham’s backing.

Now, that reimagined company — Bindwell — has raised $6 million in a seed round, co-led by General Catalyst and A Capital, with a personal check from Graham himself. Rather than selling AI tools to legacy agrochemical giants, the startup is using its own models to design new pesticide molecules in-house and license the IP directly — a shift in strategy aimed at modernizing a legacy industry still dominated by decades-old chemistry.

Pesticide use in agriculture has doubled over the last three decades, yet up to 40% of global crop production is still lost to pests and diseases every year, per the UN Food and Agriculture Organization. As pests evolve and develop resistance, farmers are forced to use increasing amounts of chemicals just to maintain the same yields — a cycle that damages ecosystems and accelerates resistance even further. Regulatory pressure is mounting, but most agrochemical companies still rely on tweaking legacy compounds. Bindwell is betting that AI can break the cycle by discovering entirely new, more targeted molecules — ones designed from scratch for modern challenges.

Founded in 2024 by Tyler Rose, 18, and Navvye Anand, 19, Bindwell adapts AI-led drug discovery techniques to agriculture, with the goal of speeding up how new pesticide molecules are identified and tested.

Bindwell began as a research project in late 2023, when Rose and Anand were students at the Wolfram Summer Research Program. They initially focused on a drug discovery AI model called PLAPT, which involved binding affinity prediction — work that was later cited in a Nature Scientific Reports paper on cancer therapeutics. In 2024, they began exploring how the same approach could be applied to pesticides.

Both founders had personal exposure to the problem. Rose learned about the challenges of pest control from his aunt, who farms in China. Anand, who has roots in Punjab, saw firsthand how limited pesticide options affected crop yields.

“Agriculture has been in our mind space,” said Rose in an interview. “That led to the realization that we can use the exact same technology that has been successful in drug discovery. We can bring that over to pesticide discovery, because the biochemistry is the same, but pesticides are such a big problem, and I feel like it’s not very focused on by most people.”

Bindwell co-founders Tyler Rose (Left) and Navvye Anand (Right)Image Credits:Bindwell

Rose and Anand entered Y Combinator’s Winter 2025 batch with plans to build AI models and sell their access to major agrochemical companies. But they did not find traction — most industry players were reluctant to adopt AI as a core part of pesticide discovery. Midway through the program, they were invited to Paul Graham’s home, where they spoke with him for about 45 minutes on the back patio.

After hearing about their challenges, Graham suggested a different approach: Rather than selling tools, they could use their own models to discover new pesticide molecules themselves. That conversation marked the beginning of Bindwell’s current direction.

“The founders [of Bindwell] will probably do alright,” he later posted on X. “They’re smart and have a good idea.”

Bindwell has developed its own AI suite designed to reduce hallucination — a common issue where models produce unreliable or unsupported outputs. The software includes Foldwell, a structure prediction model, which is a custom diffusion system inspired by DeepMind’s AlphaFold, used to identify target protein structures. It also includes PLAPT, an open source protein-ligand interaction model capable of scanning every known synthesized compound in under six hours, and APPT, a protein-protein interaction model for biopesticide screening, reported to outperform existing tools by 1.7× on the Affinity Benchmark v5.5. Moreover, the suite incorporates an uncertainty quantification system that flags when results are trustworthy and when more data is needed.

“Since we’re not selling AI models, we’re not competing with companies that sell models,” Rose told TechCrunch.

Together, Bindwell’s models can analyze “billions” of molecules, the startup said, and deliver four times faster performance than DeepMind’s AlphaFold 3.

“The way most pesticides are discovered right now is not target-based,” said Rose. “Entomologists and chemists suggest different compounds, then test them on insects. You often need to synthesize and test thousands of chemicals, which is expensive just to check for efficacy. With our AI models, you’re able to simplify the problem down to a single protein.”

The AI helps identify proteins that are unique to a specific pest but absent in humans, beneficial insects, or aquatic organisms like water fleas.

“Once you find those proteins, you can design something that binds to them and stops them from working,” Rose said.

Bindwell is currently testing the efficacy of its AI-generated molecules at its lab in San Carlos. It is also working with a third-party partner to further validate the models, though Rose declined to share details.

Rose said the startup is in early discussions with several global agrochemical firms, with its first partnership deal expected to close soon. “A year from now, we want to be entering into our licensing deals with some of these companies,” he said. Bindwell has also begun talks with stakeholders in India and China to conduct field tests.

The startup currently has a team of four, and also works with external contractors for molecule synthesis.

Bindwell’s seed round also included participation from SV Angel, alongside Graham. Prior to joining Y Combinator’s Winter 2025 batch, the startup raised a pre-seed round from Character Capital.

View original article on techcrunch.com

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Eppo lands new cash to grow its app, website and AI experimentation business

Eppo lands new cash to grow its app, website and AI experimentation business

The AI industry continues to release tons of new models, and companies looking to stay competitive are racing to adopt them for their purposes. In fact, nearly 10% of businesses plan to spend a whopping $25 million this year on AI initiatives, according to tech consulting firm Searce. But while lots of money is being spent on AI, it’s unclear the ROI is there. Half of all AI leaders aren’t sure how to calculate or demonstrate the value of AI projects, according to Gartner. Ex-Airbnb data scient

Aug 20, 2024

Stack AI wants to make it easier to build AI-fueled workflows

Stack AI wants to make it easier to build AI-fueled workflows

Stack AI’s co-founders, Antoni Rosinol and Bernardo Aceituno, were PhD studentsnat MIT wrapping up their degrees in 2022 just as large language models werenbecoming more mainstream. ChatGPT would be released to the world at the end ofnthe year, but even before that, they recognized a problem inside companiesnputting data together with […]

May 21, 2024

Onepot AI raises $13M to help make chemical drug creation easier

Onepot AI raises $13M to help make chemical drug creation easier

Onepot AI is a company that is home to the small-molecule synthesis lab POT-1.

Nov 19, 2025

Top OpenAI, Google Brain researchers set off a $300M VC frenzy for their startup Periodic Labs

Top OpenAI, Google Brain researchers set off a $300M VC frenzy for their startup Periodic Labs

When Liam Fedus announced he was quitting OpenAI, VCs swarmed. One even wrote a love letter. Here's how Felicis' Peter Deng won the deal.

Oct 20, 2025

Most Recent

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Jul 20, 2026

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

Natural raises $30M to reinvent payments for AI agents — and take on Stripe

The one-year-old startup aims to reinvent financial architecture for autonomous AI transactions.

Jul 20, 2026

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Similar Posts

Eppo lands new cash to grow its app, website and AI experimentation business

Eppo lands new cash to grow its app, website and AI experimentation business

The AI industry continues to release tons of new models, and companies looking to stay competitive are racing to adopt them for their purposes. In fact, nearly 10% of businesses plan to spend a whopping $25 million this year on AI initiatives, according to tech consulting firm Searce. But while lots of money is being spent on AI, it’s unclear the ROI is there. Half of all AI leaders aren’t sure how to calculate or demonstrate the value of AI projects, according to Gartner. Ex-Airbnb data scient

Aug 20, 2024

Stack AI wants to make it easier to build AI-fueled workflows

Stack AI wants to make it easier to build AI-fueled workflows

Stack AI’s co-founders, Antoni Rosinol and Bernardo Aceituno, were PhD studentsnat MIT wrapping up their degrees in 2022 just as large language models werenbecoming more mainstream. ChatGPT would be released to the world at the end ofnthe year, but even before that, they recognized a problem inside companiesnputting data together with […]

May 21, 2024

Onepot AI raises $13M to help make chemical drug creation easier

Onepot AI raises $13M to help make chemical drug creation easier

Onepot AI is a company that is home to the small-molecule synthesis lab POT-1.

Nov 19, 2025

Top OpenAI, Google Brain researchers set off a $300M VC frenzy for their startup Periodic Labs

Top OpenAI, Google Brain researchers set off a $300M VC frenzy for their startup Periodic Labs

When Liam Fedus announced he was quitting OpenAI, VCs swarmed. One even wrote a love letter. Here's how Felicis' Peter Deng won the deal.

Oct 20, 2025